Briefs from across the spectrum, bias-scored and cross-checked. The whole story, without the spin.
The biotech aims to become the second company to commercialize a treatment for the fatal muscle-wasting disease.
At the American Society of Gene & Cell Therapy annual meeting, in vivo CAR-T therapies are a major topic but have yet to reach clinical trials.
Researchers argue conversational AI represents a qualitatively distinct escalation of a trust paradox where rigorous institutions lose credibility while unaccountable voices gain it.
Admiral Brad Cooper directly challenges open-source claims about the extent of Iran's remaining missile and drone capabilities.
A divided Supreme Court indefinitely extended a freeze on strict new restrictions for dispensing mifepristone while the legal battle plays out.
Regenxbio's experimental Duchenne muscular dystrophy gene therapy met its primary endpoint, though two serious adverse events raise safety questions ahead of an FDA submission.
No briefs match this filter.